Effect of Fenofibrate on Sleep Apnea Syndrome

Summary

Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.

Timeline

Start

2005-09

Primary completion

2008-01

Completion

2008-01

Outcome

Mixed primary results

Stopped (Enrollment): “The study was prematurely terminated because of slow recruitment”

registry MEDIAN Placebo: 30.5 (0 to 318) Number of obstructive apneas MEDIAN Fenofibrate: 15.0 (0 to 168) Number of obstructive apneas NCT00816829 ↗

registry analysis (superiority or other test); Placebo vs Fenofibrate; p = 0.048; ANCOVA NCT00816829 ↗

registry analysis (superiority or other test); Placebo vs Fenofibrate; p = 0.007; Wilcoxon (Mann-Whitney) NCT00816829 ↗

registry analysis (superiority or other test); Placebo vs Fenofibrate; p = 0.203; ANCOVA NCT00816829 ↗

registry analysis (superiority or other test); Placebo vs Fenofibrate; p = 0.533; ANCOVA NCT00816829 ↗

Publications

• Bruckert E, Duchene E, Bonnefont-Rousselot D, Hansel B, Ansquer JC, Dubois A, Gaymard B. Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome? Curr Med Res Opin. 2010 May;26(5):1185-92. doi: 10.1185/03007991003693581.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fenofibrate	Small molecule	145 mg	—

Indications